Alphega Pharmacy UK Elevate Convention 2025: Leading the Future of Pharmacy Through Innovation, AI, and Patient-Centred Care

Alphega Pharmacy brought together more than 200 independent pharmacy professionals, partners and thought leaders for its annual conference this weekend in Birmingham. The event, hosted at the Hilton Hotel on 22 June, explored the latest in healthcare innovation, operational excellence and patient care, as well as discussions of the changing pharmacy landscape and embracing technological innovation. Attendees shared practical insights and real-world solutions shaping the future of independent pharmacy in the UK.

The conference featured a lineup of notable speakers from Perrigo, Serve First, Reckitt and Kenvue, as well as Dr Zubir Ahmed MP. Alongside this, breakout sessions took place focused on supplier perspectives, from smarter solutions from working, to elevating community pharmacists and helping patients quit smoking. Sessions also included practical case studies from Alphega members and suppliers.

As the role of community pharmacy continues to expand, the Alphega Convention acts as a catalyst for knowledge-sharing and collaboration, helping members stay ahead of clinical, operational and digital changes in primary care. Attendees left with tools and new strategies – from embracing digital solutions to enhancing patient engagement – that provided practical insights to streamline operations and strengthen their role as frontline healthcare providers within their communities.

Mandeep Mudhar, Head of Alphega, said: “This year’s Alphega Pharmacy UK Elevate Convention 2025 showed just how much opportunity exists for pharmacies that embrace innovation and patient-first thinking. It was fantastic to see so many passionate pharmacy professionals come together to share ideas and look ahead to an exciting future.”

Dr Zubir Ahmed, MP for Glasgow South West, said: “Alphega Pharmacy UK Elevate Convention was a strong reflection of the strength of community pharmacy and its vital role in shaping the future of healthcare. Alphega members are instrumental in driving the shift from hospital-based care to more community-focused services. The conference was a landmark event and I was honoured to be the keynote Westminster speaker.”

Alliance Healthcare Teams Complete 300 Mile Cross-Border Charity Cycle Challenge

Eight Alliance Healthcare team members have completed grueling 300 mile cross-border Tour D’Alliance 2025 challenge, raising over £55,000 for Theodora Children’s Charity.

From 13 to 15 June, participants from the UK and France cycled from Chessington, Surrey to Alliance Healthcare France HQ in Paris. The cross-border challenge not only celebrated international teamwork but also raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Matt Addison, VP Operations, Alliance Healthcare, who created the Tour D’Alliance series back in 2019 said: “This year we took the challenge international, and the sponsorship and support has been incredible. We were determined to raise as much as possible to help young children and their families during the most difficult times. Over £55,000 raised for Theodora Children’s Charity is an amazing amount and I am proud of the team who knew that with every painful pedal, we were doing our bit to help a very worthy cause.”

Ellen Blessington, Senior Community and Communications Fundraiser said: “We are incredibly grateful to have been supported in this year’s Tour D’Alliance. Being ill and needing medical treatment is difficult at any point in life, but when you are a child, it can be particularly confusing and frightening. Thanks to the cyclists taking on the challenge of 300 miles, over 2,400 children will receive a magical Giggle Doctor visit, helping reduce their stress and anxiety, create opportunities for play and transform their hospital experience. From all of us at Theodora Children’s Charity, including our Giggle Doctors, our heartfelt thanks go to the cyclists, drivers, sponsors and everyone who made this challenge possible!”

Teams across Alliance Healthcare supported the challenge with a teddy bear plush toy photo competition, summer garden buffet and breakfast party send-off at the Chessington site. Tour D’Alliance 2025 showcased the physical strength and spirit of the participants, reflecting Alliance Healthcare’s commitment to creating healthier futures through charitable fundraising and collective action.

Special thanks to all our sponsors and generous supporters, in particular: LCM and Mertrux. Since its origin Tour D’Alliance has now raised over £230,000 for charities.
 

Class 2 recall-PI Inhixa 12,000IU (120mg)/0.8mL solution for injection

Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-inhixa-12000iu-120mg-slash-0-dot-8ml-solution-for-injection-maxearn-limited-el-25-a-slash-27?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=225b3c3d-411e-4f22-9b63-30117bf0dac8&utm_content=immediately

MHRA drug alert date 12/06/25

Further Information

For all medical information enquiries and information on this product, please email eupvg@genreg.eu or telephone 020 7201 0421.

For stock control enquiries please email info@genesis-pharma.com or telephone 0207 201 0400.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use - Dulcolax Adult 5 mg Gastro-resistant Tablets

Opella Healthcare UK LTD has informed the MHRA that there is an error on the artwork for the outer carton of Dulcolax Adult 5mg GR Tablets (packsize 20 count). The dose instruction incorrectly states for use in 12 years and older. These general sale packs are intended for use only in adult patients (18 years and over).

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-dulcolax-adult-5-mg-gastro-resistant-tablets-opella-healthcare-uk-el-25-a-slash-26?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=3758a495-ac74-45d7-aaf0-88314480fc30&utm_content=immediately

MHRA drug alert date: 10/06/25

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email uk-medicalinformation@sanofi.com, or telephone 0800 035 2525.

Class 2 recall-Paracetamol 500mg tab (100)

Chelonia Healthcare Limited is recalling specific batches of Paracetamol 500mg Tablets (100 pots) as a precautionary measure due to contamination following a small number of complaints of discoloured tablets within the pots.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-paracetamol-500mg-tablets-chelonia-healthcare-limited-el-25-a-slash-25?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=6cffbae9-5c8f-42f8-b5b0-6cf69d34ffb1&utm_content=immediately

MHRA drug alert date 09/06/25

Further Information

For all medical information enquiries and information on this product, please email eupvg@genreg.eu or telephone 020 7201 0421.

For stock control enquiries please email info@genesis-pharma.com or telephone 0207 201 0400.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Zentiva Pharma UK Limited, Various Product

Zentiva Pharma UK Limited has informed the MHRA of an issue related to batches of various soluble or effervescent tablets.

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-zentiva-pharma-uk-limited-various-products-el-25-a-slash-24?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=0fc7bea3-f591-4a3e-8fc1-1d28e6bfa2ea&utm_content=immediately

MHRA drug alert date: 02/06/25

This is a caution in use only we are not accepting stock returns

Further Information

For all medical information enquiries and information on this product, please email Zentiva medical information via webform, email UKmedinfo@zentiva.com or telephone 0800 090 2408.

For stock control enquiries please email ukcustomerservices@zentiva.com or telephone 08448 793188.

Class 2 recall-BD ChloraPrep Clear - 1mL Applicator

Becton Dickinson UK Ltd has informed the MHRA that some units exhibit an open seal on the packaging of the applicator. This defect could increase the risk of the applicator device being contaminated with pathogens, which could lead to increased infection rates for the patients.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-bd-chloraprep-clear-1ml-applicator-becton-dickinson-uk-ltd-el-25-a-slash-22?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=523232d5-0bdd-4537-8674-58051af969ec&utm_content=immediately

MHRA drug alert date: 19/05/25

Update: 28/07/25- another batch has been included, please see below link

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-chloraprep-1ml-clear-sterile-solution-slash-applicator-becton-dickinson-uk-ltd-el-25-a-slash-36

Further Information

For all medical information enquiries and information on this product, please email safetyinformation@bd.com, or telephone 08000437546.

For stock control enquiries please email info@insightbio.com, or telephone 01707351330.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Company Led Class 2 recall-Mercaptopurine tablets 50mg

Aspen Pharma Trading Limited is recalling a specific batch of Mercaptopurine 50mg tablets as a precautionary measure due to possible microbial contamination.

Drug alert date: 16/05/25

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Various Chemidex products

Chemidex Pharma Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in their topical steroid products does not contain all the required safety information. Cartons for the products/batches listed are missing side effect information related to Visual Disturbances.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-chemidex-pharma-ltd-various-products-el-25-a-slash-21?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e243de6b-1eab-4918-8ada-2250c1d02a06&utm_content=immediately

MHRA drug alert date: 13/05/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email essentialpharmaUK@EU.ProPharmaGroup.com or telephone +44 (0)1423 850700.

For stock control enquiries please email commercial@essentialpharmagroup.com.

class 4 caution in use-Chloramphenicol Eye ointment 1% POM

Blumont Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of the batch of Chloramphenicol 1% w/w Eye Ointment (POM version only) in the below table.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-chloramphenicol-1-percent-w-slash-w-eye-ointment-blumont-pharma-limited-el-25-a-slash-20?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=a7b39a78-d068-448f-a434-38a623f0a06c&utm_content=immediately

MHRA drug alert date: 8/05/25

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email info@blumontpharma.com, or telephone 01476978568

For stock control enquiries please email manoj@blumontpharma.com, or telephone 01476978568